Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockView Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1360.00 | 2,229 Cr | 50.86 | 8.28 | 0.02 | 11.73 | 17.24 | 6.82 | ||
1586.55 | 2,131 Cr | 18.34 | 3.21 | 0.63 | 15.49 | 19.85 | 13.61 | ||
19.75 | 1,861 Cr | 21.76 | 4.48 | 0.51 | 18.42 | 24.46 | 16.02 | ||
2190.00 | 1,860 Cr | 13.58 | 5.16 | 0.50 | 15.45 | 14.34 | 20.20 | ||
2729.00 | 1,687 Cr | 29.50 | 5.13 | 0.06 | 14.62 | 15.37 | 10.49 | ||
683.55 | 1,640 Cr | 37.39 | 5.95 | 0.15 | 15.92 | 21.28 | 13.63 | ||
227.55 | 1,498 Cr | 32.94 | 5.46 | 1.79 | 15.60 | 20.59 | 14.36 | ||
| Median: 7 Co. | — | 1360.00 | 1,860 Cr | 29.50 | 5.16 | 0.50 | 15.49 | 19.85 | 13.63 |
Syncom Formulations (India) Limited operates in the Indian Pharmaceutical Industry, manufacturing and marketing over 200 pharmaceutical formulations. The company specializes in tablets, capsules, liquids, injectables, and herbal products.
Syncom has strategically expanded its manufacturing capacity over the years, notably enhancing tablet and capsule production and establishing modern facilities in Pithampur and Palghar.
The company's export operations are robust, with significant international presence across Africa and Asia. It has received notable export orders, indicating strong overseas demand.
Syncom has demonstrated commitment to modernization, as seen through expansion projects enhancing capacity and introducing advanced manufacturing equipment, indicating focus on quality and efficiency.
The introduction of a new division, Cratus Life Care, highlights Syncom's efforts to expand its operational scope and address diverse market segments, including ethical and herbal product lines.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,914 Cr
High Risk
22.4
37.9
0.4
4.5
22.52
10.21
Sales CAGR
Profit CAGR
ROE
Bearish
2
Neutral
7
Bullish
5
ROCE
Syncom Formulations (India) Ltd (SYNCOMF) is currently trading at 20.36 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Syncom Formulations (India) Limited operates in the Indian Pharmaceutical Industry, manufacturing and marketing over 200 pharmaceutical formulations. The company specializes in tablets, capsules, liquids, injectables, and herbal products. Syncom has strategically expanded its manufacturing capacity over the years, notably enhancing tablet and capsule production and establishing modern facilities in Pithampur and Palghar. The company's export operations are robust, with significant international presence across Africa and Asia. It has received notable export orders, indicating strong overseas demand. Syncom has demonstrated commitment to modernization, as seen through expansion projects enhancing capacity and introducing advanced manufacturing equipment, indicating focus on quality and efficiency. The introduction of a new division, Cratus Life Care, highlights Syncom's efforts to expand its operational scope and address diverse market segments, including ethical and herbal product lines.
Over the past 52 weeks, Syncom Formulations (India) Ltd has traded between a low of ₹10.21 and a high of ₹22.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Syncom Formulations (India) Ltd has a market capitalization of approximately 1,861.20. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Syncom Formulations (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,861.20 Cr, Syncom Formulations (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Syncom Formulations (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Syncom Formulations (India) Ltd is 21.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting is scheduled for Tuesday, August 11, 2026 at 4:00 PM IST at the company’s corporate office in Indore.
His resignation as Whole-Time Director and Director is effective August 11, 2026, and the cessation is stated to be from the close of business hours that day.
The 'Biopharma Shakti' initiative, a ₹10,000 crore program to make India a global biopharma manufacturing hub, is the most significant announcement for the pharmaceutical sector, including companies like Syncom.
Bearish
2
Neutral
7
Bullish
37
Bearish
0
Neutral
0
Bullish
32
